HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nikolai Makukhin Selected Research

MRT-92

1/2021Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nikolai Makukhin Research Topics

Disease

1Parkinson Disease (Parkinson's Disease)
01/2022
1Melanoma (Melanoma, Malignant)
01/2021
1Starvation
10/2019
1Alzheimer Disease (Alzheimer's Disease)
10/2016
1Neoplasms (Cancer)
10/2016

Drug/Important Bio-Agent (IBA)

2methionine sulfoxideIBA
10/2019 - 10/2016
1Leucine (L-Leucine)FDA Link
01/2022
1Phosphotransferases (Kinase)IBA
01/2022
1Proteolysis Targeting ChimeraIBA
01/2021
1MRT-92IBA
01/2021
1EnzymesIBA
10/2016

Therapy/Procedure

1Therapeutics
01/2021